Updated perspectives on the clinical significance of negative symptoms in patients with schizophrenia

References

• Galderisi S, Mucci A, Dollfus S, et al. EPA guidance on assessment of negative symptoms in schizophrenia. Eur Psychiatry. 2021;64(1):e23.
   PubMed Web of Science ®Google Scholar
• Correll CU, Schooler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat. 2020;16:519–534.
   PubMed Web of Science ®Google Scholar
• Marder SR, Galderisi S. The current conceptualization of negative symptoms in schizophrenia. World Psychiatry. 2017;16(1):14–24.
   PubMed Web of Science ®Google Scholar
• Maj M, van Os J, De Hert M, et al. The clinical characterization of the patient with primary psychosis aimed at personalization of management. World Psychiatry. 2021;20(1):4–33.
   PubMed Web of Science ®Google Scholar
• Novick D, Haro JM, Suarez D, et al. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res. 2009;108(1–3):223–230.
   PubMed Web of Science ®Google Scholar
• Harvey PD, Strassnig M. Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status. World Psychiatry. 2012;11(2):73–79.
   PubMed Web of Science ®Google Scholar
• Galderisi S, Rossi A, Rocca P, et al. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry. 2014;13(3):275–287.
   PubMed Web of Science ®Google Scholar
• Galderisi S, Rossi A, Rocca P, et al. Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives. Schizophr Res. 2016;175(1–3):154–160.
   PubMed Web of Science ®Google Scholar
• Galderisi S, Rucci P, Kirkpatrick B, et al. Interplay among psychopathologic variables, personal resources, context-related factors, and real-life functioning in individuals with Schizophrenia: a network analysis. JAMA Psychiatry. 2018;75(4):396–404.
   PubMed Web of Science ®Google Scholar
• Galderisi S, Rucci P, Mucci A, et al. The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and non-recovered patients. World Psychiatry. 2020;19(1):81–91.
   PubMed Web of Science ®Google Scholar
• Mucci A, Galderisi S, Gibertoni D, et al. Factors associated with real-life functioning in persons with schizophrenia in a 4-Year Follow-up Study of the Italian network for research on psychoses. JAMA Psychiatry. 2021;78(5):550–559.
   PubMed Web of Science ®Google Scholar
• Giuliani L, Giordano GM, Bucci P, et al. Improving knowledge on pathways to functional outcome in schizophrenia: main results from the Italian network for research on psychoses. Front Psychiatry. 2021;12:791117.
   PubMed Web of Science ®Google Scholar
• Galderisi S, Giordano GM. We are not ready to abandon the current schizophrenia construct, but should be prepared to do so. Schizophr Res. 2022;242:30–34.
   PubMed Web of Science ®Google Scholar
• Bucci P, Galderisi S, Mucci A, et al. Premorbid academic and social functioning in patients with schizophrenia and its associations with negative symptoms and cognition. Acta Psychiatr Scand. 2018;138(3):253–266.
   PubMed Web of Science ®Google Scholar
• Galderisi S, Kaiser S, Bitter I, et al. EPA guidance on treatment of negative symptoms in schizophrenia. Eur Psychiatry. 2021;64(1):e21.
   PubMed Web of Science ®Google Scholar
• Heckers S, Kendler KS. The evolution of Kraepelin’s nosological principles. World Psychiatry. 2020;19(3):381–388.
   PubMed Web of Science ®Google Scholar
• Galderisi S, Mucci A, Buchanan RW, et al. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry. 2018;5(8):664–677.
   PubMed Web of Science ®Google Scholar
• Ochoa S, Usall J, Cobo J, et al. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophr Res Treatment. 2012;2012:916198.
   PubMedGoogle Scholar
• Giordano GM, Bucci P, Mucci A, et al. Gender differences in clinical and psychosocial features among persons with schizophrenia: a mini review. Front Psychiatry. 2021;12:789179.
   PubMed Web of Science ®Google Scholar
• Muralidharan A, Finch A, Bowie CR, et al. Older versus middle-aged adults with schizophrenia: executive functioning and community outcomes. Schizophr Res. 2020;216:547–549.
   PubMed Web of Science ®Google Scholar
• Muralidharan A, Harvey PD, Bowie CR. Associations of age and gender with negative symptom factors and functioning among middle-aged and older adults with schizophrenia. Am J Geriatr Psychiatry. 2018;26(12):1215–1219.
   PubMed Web of Science ®Google Scholar
• Galderisi S, Mucci A, Bitter I, et al. Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial. Eur Neuropsychopharmacol. 2013;23(3):196–204.
   PubMed Web of Science ®Google Scholar
• Austin SF, Mors O, Budtz-Jørgensen E, et al. Long-term trajectories of positive and negative symptoms in first episode psychosis: a 10 year follow-up study in the OPUS cohort. Schizophr Res. 2015;168(1–2):84–91.
   PubMed Web of Science ®Google Scholar
• Hovington CL, Bodnar M, Joober R, et al. Identifying persistent negative symptoms in first episode psychosis. BMC Psychiatry. 2012;12(1):224.
   PubMedGoogle Scholar
• Bucci P, Mucci A, van Rossum IW, et al. Persistent negative symptoms in recent-onset psychosis: relationship to treatment response and psychosocial functioning. Eur Neuropsychopharmacol. 2020;34:76–86.
   PubMed Web of Science ®Google Scholar
• Quattrone D, Di Forti M, Gayer-Anderson C, et al. Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study. Psychol Med. 2019;49(8):1378–1391.
   PubMed Web of Science ®Google Scholar
• Thorup A, Petersen L, Jeppesen P, et al. Gender differences in young adults with first-episode schizophrenia spectrum disorders at baseline in the Danish OPUS study. J Nerv Ment Dis. 2007;195(5):396–405.
   PubMed Web of Science ®Google Scholar
• Barajas A, Ochoa S, Obiols JE, et al. Gender differences in individuals at high-risk of psychosis: a comprehensive literature review. ScientificWorldJournal. 2015;430735.
   PubMedGoogle Scholar
• Challis S, Nielssen O, Harris A, et al. Systematic meta-analysis of the risk factors for deliberate self-harm before and after treatment for first-episode psychosis. Acta Psychiatr Scand. 2013;127(6):442–454.
   PubMed Web of Science ®Google Scholar
• Morgan VA, Castle DJ, Jablensky AV. Do women express and experience psychosis differently from men? Epidemiological evidence from the Australian national study of low prevalence (psychotic) disorders. Aust N Z J Psychiatry. 2008;42(1):74–82.
   PubMed Web of Science ®Google Scholar
• Leclerc E, Noto C, Bressan RA, et al. Determinants of adherence to treatment in first-episode psychosis: a comprehensive review. Braz J Psychiatry. 2015;37(2):168–176.
   PubMed Web of Science ®Google Scholar
• Santesteban-Echarri O, Paino M, Rice S, et al. Predictors of functional recovery in first-episode psychosis: a systematic review and meta-analysis of longitudinal studies. Clin Psychol Rev. 2017;58:59–75.
   PubMed Web of Science ®Google Scholar
• Watson P, Zhang JP, Rizvi A, et al. A meta-analysis of factors associated with quality of life in first episode psychosis. Schizophr Res. 2018;202:26–36.
   PubMed Web of Science ®Google Scholar
• Best MW, Grossman M, Oyewumi LK, et al. Examination of the positive and negative syndrome scale factor structure and longitudinal relationships with functioning in early psychosis. Early Interv Psychiatry. 2016;10(2):165–170.
   PubMed Web of Science ®Google Scholar
• Milev P, Ho BC, Arndt S, et al. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005;162(3):495–506.
   PubMed Web of Science ®Google Scholar
• Hafner H, Maurer K, Ruhrmann S, et al. Early detection and secondary prevention of psychosis: facts and visions. Eur Arch Psychiatry Clin Neurosci. 2004;254(2):117–128.
   PubMed Web of Science ®Google Scholar
• Iyer SN, Boekestyn L, Cassidy CM, et al. Signs and symptoms in the pre-psychotic phase: description and implications for diagnostic trajectories. Psychol Med. 2008;38(8):1147–1156.
   PubMed Web of Science ®Google Scholar
• Lencz T. Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr Res. 2004;68(1):37–48.
   PubMed Web of Science ®Google Scholar
• Piskulic D, Addington J, Cadenhead KS, et al. Negative symptoms in individuals at clinical high risk of psychosis. Psychiatry Res. 2012;196(2–3):220–224.
   PubMed Web of Science ®Google Scholar
• Velthorst E, Nieman DH, Becker HE, et al. Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis. Schizophr Res. 2009;109(1–3):60–65.
   PubMed Web of Science ®Google Scholar
• Yung AR, Phillips LJ, Yuen HP, et al. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res. 2004;67(2–3):131–142.
   PubMed Web of Science ®Google Scholar
• Carrion RE, Demmin D, Auther AM, et al. Duration of attenuated positive and negative symptoms in individuals at clinical high risk: associations with risk of conversion to psychosis and functional outcome. J Psychiatr Res. 2016;81:95–101.
   PubMed Web of Science ®Google Scholar
• Demjaha A, Valmaggia L, Stahl D, et al. Disorganization/cognitive and negative symptom dimensions in the at-risk mental state predict subsequent transition to psychosis. Schizophr Bull. 2012;38(2):351–359.
   PubMed Web of Science ®Google Scholar
• Mason O, Startup M, Halpin S, et al. Risk factors for transition to first episode psychosis among individuals with ‘at-risk mental states’. Schizophr Res. 2004;71(2–3):227–237.
   PubMed Web of Science ®Google Scholar
• Zhang T, Cui H, Wei Y, et al. Neurocognitive assessments are more important among adolescents than adults for predicting psychosis in clinical high risk. Biol Psychiatry Cogn Neurosci Neuroimaging. 2022;7(1):56–65.
   PubMedGoogle Scholar
• Devoe DJ, Peterson A, Addington J. Negative symptom interventions in youth at risk of psychosis: a systematic review and network meta-analysis. Schizophr Bull. 2018;44(4):807–823.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Kim KR, Lee SY, et al. Impaired social and role function in ultra-high risk for psychosis and first-episode schizophrenia: its relations with negative symptoms. Psychiatry Investig. 2017;14(5):539–545.
   PubMed Web of Science ®Google Scholar
• Strauss GP, Pelletier-Baldelli A, Visser KF, et al. A review of negative symptom assessment strategies in youth at clinical high-risk for psychosis. Schizophr Res. 2020;222:104–112.
   PubMed Web of Science ®Google Scholar
• Ucok A, Direk N, Kaya H, et al. Relationship of negative symptom severity with cognitive symptoms and functioning in subjects at ultra-high risk for psychosis. Early Interv Psychiatry. 2021;15(4):966–974.
   PubMed Web of Science ®Google Scholar
• Glenthoj LB, Jepsen JR, Hjorthoj C, et al. Negative symptoms mediate the relationship between neurocognition and function in individuals at ultrahigh risk for psychosis. Acta Psychiatr Scand. 2017;135(3):250–258.
   PubMed Web of Science ®Google Scholar
• Schlosser DA, Campellone TR, Biagianti B, et al. Modeling the role of negative symptoms in determining social functioning in individuals at clinical high risk of psychosis. Schizophr Res. 2015;169(1–3):204–208.
   PubMed Web of Science ®Google Scholar
• Giordano GM, Palumbo D, Pontillo M, et al. Negative symptom domains in children and adolescents at ultra-high risk for psychosis: association with real-life functioning. Schizophrenia Bulletin Open. 2022;3(1).
   Google Scholar
• Kirkpatrick B, Fenton WS, Carpenter WT Jr., et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):214–219.
   PubMed Web of Science ®Google Scholar
• Heerey EA, Gold JM. Patients with schizophrenia demonstrate dissociation between affective experience and motivated behavior. J Abnorm Psychol. 2007;116(2):268–278.
   PubMed Web of Science ®Google Scholar
• Waltz JA, Frank MJ, Robinson BM, et al. Selective reinforcement learning deficits in schizophrenia support predictions from computational models of striatal-cortical dysfunction. Biol Psychiatry. 2007;62(7):756–764.
   PubMed Web of Science ®Google Scholar
• Kring AM, Moran EK. Emotional response deficits in schizophrenia: insights from affective science. Schizophr Bull. 2008;34(5):819–834.
   PubMed Web of Science ®Google Scholar
• Barch DM, Dowd EC. Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions. Schizophr Bull. 2010;36(5):919–934.
   PubMed Web of Science ®Google Scholar
• Cohen AS, Minor KS. Emotional experience in patients with schizophrenia revisited: meta-analysis of laboratory studies. Schizophr Bull. 2010;36(1):143–150.
   PubMed Web of Science ®Google Scholar
• Foussias G, Remington G. Negative symptoms in schizophrenia: avolition and Occam’s razor. Schizophr Bull. 2010;36(2):359–369.
   PubMed Web of Science ®Google Scholar
• Dowd EC, Barch DM. Pavlovian reward prediction and receipt in schizophrenia: relationship to anhedonia. PLoS One. 2012;7(5):e35622.
   PubMed Web of Science ®Google Scholar
• Simpson EH, Waltz JA, Kellendonk C, et al. Schizophrenia in translation: dissecting motivation in schizophrenia and rodents. Schizophr Bull. 2012;38(6):1111–1117.
   PubMed Web of Science ®Google Scholar
• Strauss GP. The emotion paradox of anhedonia in schizophrenia: or is it? Schizophr Bull. 2013;39(2):247–250.
   PubMed Web of Science ®Google Scholar
• Morris RW, Quail S, Griffiths KR, et al. Corticostriatal control of goal-directed action is impaired in schizophrenia. Biol Psychiatry. 2015;77(2):187–195.
   PubMed Web of Science ®Google Scholar
• Knutson B, Fong GW, Adams CM, et al. Dissociation of reward anticipation and outcome with event-related fMRI. Neuroreport. 2001;12(17):3683–3687.
   PubMed Web of Science ®Google Scholar
• Horan WP, Kring AM, Blanchard JJ. Anhedonia in schizophrenia: a review of assessment strategies. Schizophr Bull. 2006;32(2):259–273.
   PubMed Web of Science ®Google Scholar
• Gard DE, Kring AM, Gard MG, et al. Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res. 2007;93(1–3):253–260.
   PubMed Web of Science ®Google Scholar
• Blanchard JJ, Kring AM, Horan WP, et al. Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia. Schizophr Bull. 2011;37(2):291–299.
   PubMed Web of Science ®Google Scholar
• Gold JM, Waltz JA, Matveeva TM, et al. Negative symptoms and the failure to represent the expected reward value of actions: behavioral and computational modeling evidence. Arch Gen Psychiatry. 2012;69(2):129–138.
   PubMed Web of Science ®Google Scholar
• Horan WP, Kring AM, Gur RE, et al. Development and psychometric validation of the clinical assessment interview for negative symptoms (CAINS). Schizophr Res. 2011;132(2–3):140–145.
   PubMed Web of Science ®Google Scholar
• Strauss GP, Horan WP, Kirkpatrick B, et al. Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J Psychiatr Res. 2013;47(6):783–790.
   PubMed Web of Science ®Google Scholar
• Kaiser S, Lyne J, Agartz I, et al. Individual negative symptoms and domains - relevance for assessment, pathomechanisms and treatment. Schizophr Res. 2017;186:39–45.
   PubMed Web of Science ®Google Scholar
• Gaebel W, Falkai P, Hasan A. The revised German evidence- and consensus-based schizophrenia guideline. World Psychiatry. 2020;19(1):117–119.
   PubMed Web of Science ®Google Scholar
• Peralta V, Gil-Berrozpe GJ, Sanchez-Torres A, et al. Clinical relevance of general and specific dimensions in bifactor models of psychotic disorders. World Psychiatry. 2021;20(2):306–307.
   PubMed Web of Science ®Google Scholar
• Strauss GP, Ahmed AO, Young JW, et al. Reconsidering the latent structure of negative symptoms in schizophrenia: a review of evidence supporting the 5 consensus domains. Schizophr Bull. 2019;45(4):725–729.
   PubMed Web of Science ®Google Scholar
• Strauss GP, Esfahlani FZ, Galderisi S, et al. Network analysis reveals the latent structure of negative symptoms in schizophrenia. Schizophr Bull. 2019;45(5):1033–1041.
   PubMed Web of Science ®Google Scholar
• Strauss GP, Nunez A, Ahmed AO, et al. The latent structure of negative symptoms in schizophrenia. JAMA Psychiatry. 2018;75(12):1271–1279.
   PubMed Web of Science ®Google Scholar
• Ahmed AO, Kirkpatrick B, Galderisi S, et al. Cross-cultural validation of the 5-factor structure of negative symptoms in schizophrenia. Schizophr Bull. 2019;45(2):305–314.
   PubMed Web of Science ®Google Scholar
• Mucci A, Vignapiano A, Bitter I, et al. A large European, multicenter, multinational validation study of the brief negative symptom scale. Eur Neuropsychopharmacol. 2019;29(8):947–959.
   PubMed Web of Science ®Google Scholar
• Dollfus S, Mucci A, Giordano GM, et al. European validation of the Self-Evaluation of Negative Symptoms (SNS): a large multinational and multicenter study. Front Psychiatry. 2022;13:826465.
   PubMed Web of Science ®Google Scholar
• Beck AT, Himelstein R, Bredemeier K, et al. What accounts for poor functioning in people with schizophrenia: a re-evaluation of the contributions of neurocognitive v. attitudinal and motivational factors. Psychol Med. 2018;48(16):2776–2785.
   PubMed Web of Science ®Google Scholar
• Foussias G, Agid O, Fervaha G, et al. Negative symptoms of schizophrenia: clinical features, relevance to real world functioning and specificity versus other CNS disorders. Eur Neuropsychopharmacol. 2014;24(5):693–709.
   PubMed Web of Science ®Google Scholar
• Chang WC, Hui CL, Chan SK, et al. Impact of avolition and cognitive impairment on functional outcome in first-episode schizophrenia-spectrum disorder: a prospective one-year follow-up study. Schizophr Res. 2016;170(2–3):318–321.
   PubMed Web of Science ®Google Scholar
• Ahmed AO, Murphy CF, Latoussakis V, et al. An examination of neurocognition and symptoms as predictors of post-hospital community tenure in treatment resistant schizophrenia. Psychiatry Res. 2016;236:47–52.
   PubMed Web of Science ®Google Scholar
• Rapado-Castro M, Soutullo C, Fraguas D, et al. Predominance of symptoms over time in early-onset psychosis: a principal component factor analysis of the positive and negative syndrome scale. J Clin Psychiatry. 2010;71(3):327–337.
   PubMed Web of Science ®Google Scholar
• Langeveld J, Andreassen OA, Auestad B, et al. Is there an optimal factor structure of the positive and negative syndrome scale in patients with first-episode psychosis? Scand J Psychol. 2013;54(2):160–165.
   PubMed Web of Science ®Google Scholar
• Tibber MS, Kirkbride JB, Joyce EM, et al. The component structure of the scales for the assessment of positive and negative symptoms in first-episode psychosis and its dependence on variations in analytic methods. Psychiatry Res. 2018;270:869–879.
   PubMed Web of Science ®Google Scholar
• Lyne J, Renwick L, Grant T, et al. Scale for the Assessment of Negative Symptoms structure in first episode psychosis. Psychiatry Res. 2013;210(3):1191–1197.
   PubMed Web of Science ®Google Scholar
• Pelizza L, Landi G, Pellegrini C, et al. Negative symptom configuration in first episode Schizophrenia: findings from the “Parma Early Psychosis” program. Nord J Psychiatry. 2020;74(4):251–258.
   PubMed Web of Science ®Google Scholar
• Pelizza L, Azzali S, Paterlini F, et al. Negative symptom dimensions in first episode psychosis: is there a difference between schizophrenia and non-schizophrenia spectrum disorders? Early Interv Psychiatry. 2021;15(6):1513–1521.
   PubMed Web of Science ®Google Scholar
• Pelizza L, Maestri D, Leuci E, et al. Negative symptom configuration within and outside schizophrenia spectrum disorders: results from the “parma early psychosis” program. Psychiatry Res. 2020;294:113519.
   PubMed Web of Science ®Google Scholar
• Lam M, Abdul Rashid NA, Lee SA, et al. Baseline social amotivation predicts 1-year functioning in UHR subjects: a validation and prospective investigation. Eur Neuropsychopharmacol. 2015;25(12):2187–2196.
   PubMed Web of Science ®Google Scholar
• Azis M, Strauss GP, Walker E, et al. Factor analysis of negative symptom items in the structured interview for prodromal syndromes. Schizophr Bull. 2019;45(5):1042–1050.
   PubMed Web of Science ®Google Scholar
• Chang WC, Lee HC, Chan SI, et al. Negative symptom dimensions differentially impact on functioning in individuals at-risk for psychosis. Schizophr Res. 2018;202:310–315.
   PubMed Web of Science ®Google Scholar
• Chang WC, Strauss GP, Ahmed AO, et al. The latent structure of negative symptoms in individuals with attenuated psychosis syndrome and early psychosis: support for the 5 consensus domains. Schizophr Bull. 2021;47(2):386–394.
   PubMed Web of Science ®Google Scholar
• Hawkins KA, McGlashan TH, Quinlan D, et al. Factorial structure of the Scale of Prodromal Symptoms. Schizophr Res. 2004;68(2–3):339–347.
   PubMed Web of Science ®Google Scholar
• Tso IF, Taylor SF, Grove TB, et al. Factor analysis of the scale of prodromal symptoms: data from the early detection and intervention for the prevention of psychosis program. Early Interv Psychiatry. 2017;11(1):14–22.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276.
   PubMed Web of Science ®Google Scholar
• Andreasen NC. The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry Suppl.1989; 155(7):49–58.
   Google Scholar
• Andreasen NC. The scale for the assessment of positive symptoms (SAPS). Iowa City Iowa: The University of Iowa; 1984.
   Google Scholar
• Chang WC, Kwong VW, Hui CL, et al. Relationship of amotivation to neurocognition, self-efficacy and functioning in first-episode psychosis: a structural equation modeling approach. Psychol Med. 2017;47(4):755–765.
   PubMed Web of Science ®Google Scholar
• Chang WC, Kwong VW, Chan GH, et al. Prediction of motivational impairment: 12-month follow-up of the randomized-controlled trial on extended early intervention for first-episode psychosis. Eur Psychiatry. 2017;41(1):37–41.
   PubMedGoogle Scholar
• Chang WC, Wong CSM, Pcf O, et al. Inter-relationships among psychopathology, premorbid adjustment, cognition and psychosocial functioning in first-episode psychosis: a network analysis approach. Psychol Med. 2020;50(12):2019–2027.
   PubMed Web of Science ®Google Scholar
• Yung AR, Yuen HP, McGorry PD, et al. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust N Z J Psychiatry. 2005;39(11–12):964–971.
   PubMed Web of Science ®Google Scholar
• Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29(4):703–715.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B, Strauss GP, Nguyen L, et al. The brief negative symptom scale: psychometric properties. Schizophr Bull. 2011;37(2):300–305.
   PubMed Web of Science ®Google Scholar
• Strauss GP, Nuñez A, Ahmed AO, et al. The latent structure of negative symptoms in schizophrenia. JAMA Psychiatry. 2018;75(12):1271–1279.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B, A M, Galderisi S. Primary, enduring negative symptoms: an update on research. Schizophr Bull. 2017;43(4):730–736.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B, Buchanan RW, Ross DE, et al. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry. 2001;58(2):165–171.
   PubMed Web of Science ®Google Scholar
• Mucci A, Merlotti E, Üçok A, et al. Primary and persistent negative symptoms: concepts, assessments and neurobiological bases. Schizophr Res. 2017;186:19–28.
   PubMed Web of Science ®Google Scholar
• Carpenter WT Jr., Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry. 1988;145(5):578–583.
   PubMed Web of Science ®Google Scholar
• Galderisi S, Maj M, Mucci A, et al. Historical, psychopathological, neurological, and neuropsychological aspects of deficit schizophrenia: a multicenter study. Am J Psychiatry. 2002;159(6):983–990.
   PubMed Web of Science ®Google Scholar
• Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull. 2007;33(4):1013–1022.
   PubMed Web of Science ®Google Scholar
• Galderisi S, Maj M. Deficit schizophrenia: an overview of clinical, biological and treatment aspects. Eur Psychiatry. 2009;24(8):493–500.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B. Progress in the study of negative symptoms. Schizophr Bull. 2014;40(Suppl 2):S101–6.
   PubMedGoogle Scholar
• Kirkpatrick B, Miller B, García-Rizo C, et al. Schizophrenia: a systemic disorder. Clin Schizophr Relat Psychoses. 2014;8(2):73–79.
   PubMedGoogle Scholar
• Galderisi S, Merlotti E, Mucci A. Neurobiological background of negative symptoms. Eur Arch Psychiatry Clin Neurosci. 2015;265(7):543–558.
   PubMed Web of Science ®Google Scholar
• Bucci P, Galderisi S. Categorizing and assessing negative symptoms. Curr Opin Psychiatry. 2017;30(3):201–208.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B, Galderisi S. Deficit schizophrenia: an update. World Psychiatry. 2008;7(3):143–147.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick B, Buchanan RW, McKenney PD, et al. The Schedule for the Deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 1989;30(2):119–123.
   PubMed Web of Science ®Google Scholar
• Kumari S, Malik M, Florival C, et al. An assessment of five (PANSS,SAPS,SANS,NSA-16, CGI-SCH) commonly used symptoms rating scales in schizophrenia and comparison to newer scales (CAINS, BNSS). Journal of Addiction Research & Therapy. 2017;8(3):324.
   Google Scholar
• Mucci A, Galderisi S, Merlotti E, et al. The brief negative symptom scale (BNSS): independent validation in a large sample of Italian patients with schizophrenia. Eur Psychiatry. 2015;30(5):641–647.
   PubMed Web of Science ®Google Scholar
• Kring AM, Gur RE, Blanchard JJ, et al. The clinical assessment interview for negative symptoms (CAINS): final development and validation. Am J Psychiatry. 2013;170(2):165–172.
   PubMed Web of Science ®Google Scholar
• Ang MS, Rekhi G, Lee J. Validation of the brief negative symptom scale and its association with functioning. Schizophr Res. 2019;208:97–104.
   PubMed Web of Science ®Google Scholar
• Nazlı I P, Ergül C, Ö A, et al. Validation of Turkish version of brief negative symptom scale. Int J Psychiatry Clin Pract. 2016;20(4):265–271.
   PubMed Web of Science ®Google Scholar
• Gehr J, Glenthøj B, Ødegaard Nielsen M. Validation of the Danish version of the brief negative symptom scale. Nord J Psychiatry. 2019;73(7):425–432.
   PubMed Web of Science ®Google Scholar
• Wójciak P, Górna K, Domowicz K, et al. Polish version of the brief negative symptom scale (BNSS). Psychiatr Pol. 2019;53(3):541–549.
   PubMed Web of Science ®Google Scholar
• Bischof M, Obermann C, Hartmann MN, et al. The brief negative symptom scale: validation of the German translation and convergent validity with self-rated anhedonia and observer-rated apathy. BMC Psychiatry. 2016;16(1):415.
   PubMedGoogle Scholar
• Mané A, García-Rizo C, Garcia-Portilla MP, et al. Spanish adaptation and validation of the brief negative symptoms scale. Compr Psychiatry. 2014;55(7):1726–1729.
   PubMed Web of Science ®Google Scholar
• Chan RC, Shi C, Lui SS, et al. Validation of the Chinese version of the clinical assessment interview for negative symptoms (CAINS): a preliminary report. Front Psychol. 2015;6:7.
   PubMed Web of Science ®Google Scholar
• Xie DJ, Shi HS, Lui SSY, et al. Cross cultural validation and extension of the clinical assessment interview for negative symptoms (CAINS) in the Chinese context: evidence from a spectrum perspective. Schizophr Bull. 2018;44(suppl_2):S547–s55.
   PubMedGoogle Scholar
• Jung SI, Woo J, Kim YT, et al. Validation of the Korean-version of the clinical assessment interview for negative symptoms of schizophrenia (CAINS). J Korean Med Sci. 2016;31(7):1114–1120.
   PubMed Web of Science ®Google Scholar
• Valiente-Gómez A, Mezquida G, Romaguera A, et al. Validation of the Spanish version of the clinical assessment for negative symptoms (CAINS). Schizophr Res. 2015;166(1–3):104–109.
   PubMed Web of Science ®Google Scholar
• Engel M, Fritzsche A, Lincoln TM. Validation of the German version of the clinical assessment interview for negative symptoms (CAINS). Psychiatry Res. 2014;220(1–2):659–663.
   PubMed Web of Science ®Google Scholar
• Dollfus S, Mach C, Morello R. Self-evaluation of negative symptoms: a novel tool to assess negative symptoms. Schizophr Bull. 2016;42(3):571–578.
   PubMed Web of Science ®Google Scholar
• Dollfus S, Mucci A, Giordano GM, et al. European validation of the Self-Evaluation of Negative Symptoms (SNS): a large multinational and multicenter study. Frontiers in psychiatry. 2022; 13:826465. DOI:10.3389/fpsyt.2022.826465.
   PubMed Web of Science ®Google Scholar
• Tatsumi K, Kirkpatrick B, Strauss GP, et al. The brief negative symptom scale in translation: a review of psychometric properties and beyond. Eur Neuropsychopharmacol. 2020;33:36–44.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Testal JF, Perona-Garcelán S, Dollfus S, et al. Spanish validation of the self-evaluation of negative symptoms scale SNS in an adolescent population. BMC Psychiatry. 2019;19(1):327.
   PubMed Web of Science ®Google Scholar
• Strauss GP, Chapman HC. Preliminary psychometric properties of the brief negative symptom scale in youth at clinical high-risk for psychosis. Schizophr Res. 2018;193:435–437.
   PubMed Web of Science ®Google Scholar
• Gur RE, March M, Calkins ME, et al. Negative symptoms in youths with psychosis spectrum features: complementary scales in relation to neurocognitive performance and function. Schizophr Res. 2015;166(1–3):322–327.
   PubMed Web of Science ®Google Scholar
• Pelletier-Baldelli A, Strauss GP, Visser KH, et al. Initial development and preliminary psychometric properties of the Prodromal Inventory of Negative Symptoms (PINS). Schizophr Res. 2017;189:43–49.
   PubMed Web of Science ®Google Scholar
• Kotov R, Jonas KG, Carpenter WT, et al. Validity and utility of Hierarchical Taxonomy of Psychopathology (HiTOP): i. Psychosis Superspectrum. World Psychiatry. 2020;19(2):151–172.
   PubMed Web of Science ®Google Scholar
• Krueger RF, Hobbs KA, Conway CC, et al. Validity and utility of Hierarchical Taxonomy of Psychopathology (HiTOP): II. Externalizing Superspectrum. World Psychiatry. 2021;20(2):171–193.
   PubMed Web of Science ®Google Scholar
• Lahey BB, Moore TM, Kaczkurkin AN, et al. Hierarchical models of psychopathology: empirical support, implications, and remaining issues. World Psychiatry. 2021;20(1):57–63.
   PubMed Web of Science ®Google Scholar
• First MB, Gaebel W, Maj M, et al. An organization- and category-level comparison of diagnostic requirements for mental disorders in ICD-11 and DSM-5. World Psychiatry. 2021;20(1):34–51.
   PubMed Web of Science ®Google Scholar
• Amodio A, Quarantelli M, Mucci A, et al. Avolition-apathy and white matter connectivity in schizophrenia: reduced fractional anisotropy between amygdala and insular cortex. Clin EEG Neurosci. 2018;49(1):55–65.
   PubMed Web of Science ®Google Scholar
• Giordano GM, Pezzella P, Quarantelli M, et al. Investigating the relationship between white matter connectivity and motivational circuits in subjects with deficit schizophrenia: a Diffusion Tensor Imaging (DTI) study. J Clin Med. 2021;11(1):61.
   PubMed Web of Science ®Google Scholar
• Giordano GM, Stanziano M, Papa M, et al. Functional connectivity of the ventral tegmental area and avolition in subjects with schizophrenia: a resting state functional MRI study. Eur Neuropsychopharmacol. 2018;28(5):589–602.
   PubMed Web of Science ®Google Scholar
• Mucci A, Dima D, Soricelli A, et al. Is avolition in schizophrenia associated with a deficit of dorsal caudate activity? A functional magnetic resonance imaging study during reward anticipation and feedback. Psychol Med. 2015;45(8):1765–1778.
   PubMed Web of Science ®Google Scholar
• McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020;19(1):15–33.
   PubMed Web of Science ®Google Scholar
• Giordano GM, Perrottelli A, Mucci A, et al. Investigating the relationships of p3b with negative symptoms and neurocognition in subjects with chronic schizophrenia. Brain Sci. 2021;11(12):1632.
   PubMed Web of Science ®Google Scholar
• Giordano GM, Koenig T, Mucci A, et al. Neurophysiological correlates of avolition-apathy in schizophrenia: a resting-EEG microstates study. NeuroImage Clin. 2018;20:627–636.
   PubMed Web of Science ®Google Scholar
• Galderisi S, Caputo F, Giordano GM, et al. Aetiopathological mechanisms of negative symptoms in schizophrenia. Die Psychiatrie. 2016;13(3):121–129.
   Google Scholar
• Menon V. Brain networks and cognitive impairment in psychiatric disorders. World Psychiatry. 2020;19(3):309–310.
   PubMed Web of Science ®Google Scholar
• Sanislow CA. RDoC at 10: changing the discourse for psychopathology. World Psychiatry. 2020;19(3):311–312.
   PubMed Web of Science ®Google Scholar
• Harvey PD, Strassnig MT, Silberstein J. Prediction of disability in schizophrenia: symptoms, cognition, and self-assessment. J Exp Psychopathol. 2019;10(3):2043808719865693.
   Web of Science ®Google Scholar
• Miller EM, Shankar MU, Knutson B, et al. Dissociating motivation from reward in human striatal activity. J Cogn Neurosci. 2014;26(5):1075–1084.
   PubMed Web of Science ®Google Scholar
• Bissonette GB, Roesch MR. Development and function of the midbrain dopamine system: what we know and what we need to. Genes Brain Behav. 2016;15(1):62–73.
   PubMed Web of Science ®Google Scholar
• Bissonette GB, Roesch MR. Neurophysiology of reward-guided behavior: correlates related to predictions, value, motivation, errors, attention, and action. Curr Top Behav Neurosci. 2016;27:199–230.
   PubMedGoogle Scholar
• O’Doherty JP. Multiple systems for the motivational control of behavior and associated neural substrates in humans. Curr Top Behav Neurosci. 2016;27:291–312.
   PubMedGoogle Scholar
• Galderisi S, Bucci P, Mucci A, et al. Categorical and dimensional approaches to negative symptoms of schizophrenia: focus on long-term stability and functional outcome. Schizophr Res. 2013;147(1):157–162.
   PubMed Web of Science ®Google Scholar
• Kirschner M, Aleman A, Kaiser S. Secondary negative symptoms — a review of mechanisms, assessment and treatment. Schizophr Res. 2017;186:29–38.
   PubMed Web of Science ®Google Scholar
• Giordano GM, Brando F, Perrottelli A, et al. Tracing links between early auditory information processing and negative symptoms in schizophrenia: an ERP study. Front Psychiatry. 2021;12:790745.
   PubMed Web of Science ®Google Scholar
• Moritz S, Silverstein SM, Dietrichkeit M, et al. Neurocognitive deficits in schizophrenia are likely to be less severe and less related to the disorder than previously thought. World Psychiatry. 2020;19(2):254–255.
   PubMed Web of Science ®Google Scholar
• Collo G, Mucci A, Giordano GM, et al. Negative symptoms of schizophrenia and dopaminergic transmission: translational models and perspectives opened by ipsc techniques. Front Neurosci. 2020;14:632.
   PubMed Web of Science ®Google Scholar
• Noh H, Shao Z, Coyle JT, et al. Modeling schizophrenia pathogenesis using patient-derived induced pluripotent stem cells (iPSCs). Biochim Biophys Acta Mol Basis Dis. 2017;1863(9):2382–2387.
   PubMed Web of Science ®Google Scholar
• Rastgar N. Schizophrenia; recent cognitive and treatment approaches using induced pluripotent stem cells. Int Clin Neurosci J. 2020;7(4):171–178.
   Google Scholar
• Giordano GM, Pezzella P, Perrottelli A, et al. Die “Präzisionspsychiatrie” muss Teil der “personalisierten Psychiatrie” werden. Fortschr Neurol Psychiatr. 2020;88(12):767–772.
   PubMedGoogle Scholar
• Sun Y, Zhou W, Chen L, et al. Omics in schizophrenia: current progress and future directions of antipsychotic treatments. Journal of Bio-X Research. 2019;2(4):145–152.
   Google Scholar
• Guan F, Ni T, Zhu W, et al. Integrative omics of schizophrenia: from genetic determinants to clinical classification and risk prediction. Mol Psychiatry. 2022;27(1):113–126.
   PubMed Web of Science ®Google Scholar
• Kauppi K, Rosenthal SB, Lo MT, et al. Revisiting antipsychotic drug actions through gene networks associated with schizophrenia. Am J Psychiatry. 2018;175(7):674–682.
   PubMed Web of Science ®Google Scholar
• Ni P, Noh H, Park GH, et al. Correction: iPSC-derived homogeneous populations of developing schizophrenia cortical interneurons have compromised mitochondrial function. Mol Psychiatry. 2020;25(11):3103–3104.
   PubMed Web of Science ®Google Scholar
• Lyne J, Renwick L, O’Donoghue B, et al. Negative symptom domain prevalence across diagnostic boundaries: the relevance of diagnostic shifts. Psychiatry Res. 2015;228(3):347–354.
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41.
   PubMed Web of Science ®Google Scholar
• Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152–163.
   PubMed Web of Science ®Google Scholar
• Fusar-Poli P, Papanastasiou E, Stahl D, et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. 2015;41(4):892–899.
   PubMed Web of Science ®Google Scholar
• Krause M, Zhu Y, Huhn M, et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2018;268(7):625–639.
   PubMed Web of Science ®Google Scholar
• Alvarez E, Ciudad A, Olivares JM, et al. A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia. J Clin Psychopharmacol. 2006;26(3):238–249.
   PubMed Web of Science ®Google Scholar
• Riedel M, Müller N, Strassnig M, et al. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci. 2005;255(6):432–437.
   PubMed Web of Science ®Google Scholar
• Abbas AI, Hedlund PB, Huang XP, et al. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl). 2009;205(1):119–128.
   PubMed Web of Science ®Google Scholar
• Edinoff A, Ruoff MT, Ghaffar YT, et al. Cariprazine to treat schizophrenia and bipolar disorder in adults. Psychopharmacol Bull. 2020;50(4):83–117.
   PubMedGoogle Scholar
• Fleischhacker W, Galderisi S, Laszlovszky I, et al. The efficacy of cariprazine in negative symptoms of schizophrenia: post hoc analyses of PANSS individual items and PANSS-derived factors. Eur Psychiatry. 2019;58:1–9.
   PubMed Web of Science ®Google Scholar
• Leggio GM, Bucolo C, Platania CBM, et al. Current drug treatments targeting dopamine D3 receptor. Pharmacol Ther. 2016;165:164–177.
   PubMed Web of Science ®Google Scholar
• Maramai S, Gemma S, Brogi S, et al. Dopamine D3 receptor antagonists as potential therapeutics for the treatment of neurological diseases. Front Neurosci. 2016;10:451.
   PubMed Web of Science ®Google Scholar
• Németh G, Laszlovszky I, Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389(10074):1103–1113.
   PubMed Web of Science ®Google Scholar
• Sokoloff P, Le Foll B. The dopamine D3 receptor, a quarter century later. Eur J Neurosci. 2017;45(1):2–19.
   PubMed Web of Science ®Google Scholar
• Torrisi SA, Salomone S, Geraci F, et al. Buspirone counteracts MK-801-induced schizophrenia-like phenotypes through Dopamine D(3) receptor blockade. Front Pharmacol. 2017;8:710.
   PubMed Web of Science ®Google Scholar
• Fleischhacker W, Galderisi S, Laszlovszky I, et al. The efficacy of cariprazine in negative symptoms of schizophrenia: post hoc analyses of PANSS individual items and PANSS-derived factors. Eur Psychiatry. 2019;58:1–9.
   PubMed Web of Science ®Google Scholar
• Dedic N, Jones PG, Hopkins SC, et al. SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action. J Pharmacol Exp Ther. 2019;371(1):1–14.
   PubMed Web of Science ®Google Scholar
• Davidson M, Saoud J, Staner C, et al. Efficacy and safety of MIN-101: a 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia. Am J Psychiatry. 2017;174(12):1195–1202.
   PubMed Web of Science ®Google Scholar
• Kokkinou M, Irvine EE, Bonsall DR, et al. Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine. Mol Psychiatry. 2021;26(6):2562–2576.
   PubMed Web of Science ®Google Scholar
• Davidson M, Saoud J, Staner C, et al. Efficacy and safety of roluperidone for the treatment of negative symptoms of schizophrenia. Schizophr Bull. 2022; (3):609–619.
   PubMed Web of Science ®Google Scholar
• Harvey PD, Saoud JB, Luthringer R, et al. Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score: reduced emotional experience and reduced emotional expression. Schizophr Res. 2020;215:352–356.
   PubMed Web of Science ®Google Scholar
• Aleman A, Enriquez-Geppert S, Knegtering H, et al. Moderate effects of noninvasive brain stimulation of the frontal cortex for improving negative symptoms in schizophrenia: meta-analysis of controlled trials. Neurosci Biobehav Rev. 2018;89:111–118.
   PubMed Web of Science ®Google Scholar
• Kennedy NI, Lee WH, Frangou S. Efficacy of non-invasive brain stimulation on the symptom dimensions of schizophrenia: a meta-analysis of randomized controlled trials. Eur Psychiatry. 2018;49:69–77.
   PubMed Web of Science ®Google Scholar
• Osoegawa C, Gomes JS, Grigolon RB, et al. Non-invasive brain stimulation for negative symptoms in schizophrenia: an updated systematic review and meta-analysis. Schizophr Res. 2018;197:34–44.
   PubMed Web of Science ®Google Scholar
• Wobrock T, Guse B, Cordes J, et al. Left prefrontal high-frequency repetitive transcranial magnetic stimulation for the treatment of schizophrenia with predominant negative symptoms: a sham-controlled, randomized multicenter trial. Biol Psychiatry. 2015;77(11):979–988.
   PubMed Web of Science ®Google Scholar
• Turner DT, van der Gaag M, Karyotaki E, et al. Psychological interventions for psychosis: a meta-analysis of comparative outcome studies. Am J Psychiatry. 2014;171(5):523–538.
   PubMed Web of Science ®Google Scholar
• Turner DT, McGlanaghy E, Cuijpers P, et al. A Meta-Analysis of Social Skills Training and Related Interventions for Psychosis. Schizophr Bull. 2018;44(3):475–491.
   PubMed Web of Science ®Google Scholar
• Lutgens D, Gariepy G, Malla A. Psychological and psychosocial interventions for negative symptoms in psychosis: systematic review and meta-analysis. Br J Psychiatry. 2017;210(5):324–332.
   PubMed Web of Science ®Google Scholar
• Cella M, Preti A, Edwards C, et al. Cognitive remediation for negative symptoms of schizophrenia: a network meta-analysis. Clin Psychol Rev. 2017;52:43–51.
   PubMed Web of Science ®Google Scholar
• Cella M, Stahl D, Morris S, et al. Effects of cognitive remediation on negative symptoms dimensions: exploring the role of working memory. Psychol Med. 2017;47(15):1–9.
   PubMed Web of Science ®Google Scholar
• Vita A, Barlati S, Ceraso A, et al. Acceptability of cognitive remediation for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Psychol Med. 2022;1–11.
   Web of Science ®Google Scholar
• Glenthoj LB, Mariegaard LS, Fagerlund B, et al. Effectiveness of cognitive remediation in the ultra-high risk state for psychosis. World Psychiatry. 2020;19(3):401–402.
   PubMed Web of Science ®Google Scholar
• Priebe S, Savill M, Wykes T, et al. Effectiveness of group body psychotherapy for negative symptoms of schizophrenia: multicentre randomised controlled trial. Br J Psychiatry. 2016;209(1):54–61.
   PubMed Web of Science ®Google Scholar
• Sabe M, Sentissi O, Kaiser S. Meditation-based mind-body therapies for negative symptoms of schizophrenia: systematic review of randomized controlled trials and meta-analysis. Schizophr Res. 2019;212:15–25.
   PubMed Web of Science ®Google Scholar
• Attard A, Larkin M. Art therapy for people with psychosis: a narrative review of the literature. Lancet Psychiatry. 2016;3(11):1067–1078.
   PubMed Web of Science ®Google Scholar
• Bastiampillai T, Allison S, Gupta A. NICE guidelines for schizophrenia: can art therapy be justified? Lancet Psychiatry. 2016;3(11):1016–1017.
   PubMed Web of Science ®Google Scholar
• Dauwan M, Begemann MJ, Heringa SM, et al. Exercise improves clinical symptoms, quality of life, global functioning, and depression in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2016;42(3):588–599.
   PubMed Web of Science ®Google Scholar
• Sabe M, Kaiser S, Sentissi O. Physical exercise for negative symptoms of schizophrenia: systematic review of randomized controlled trials and meta-analysis. Gen Hosp Psychiatry. 2020;62:13–20.
   PubMed Web of Science ®Google Scholar
• Vogel JS, van der Gaag M, Slofstra C, et al. The effect of mind-body and aerobic exercise on negative symptoms in schizophrenia: a meta-analysis. Psychiatry Res. 2019;279:295–305.
   PubMed Web of Science ®Google Scholar
• Strauss GP, Cohen AS. A transdiagnostic review of negative symptom phenomenology and etiology. Schizophr Bull. 2017;43(4):712–719.
   PubMed Web of Science ®Google Scholar
• Chekroud AM, Bondar J, Delgadillo J, et al. The promise of machine learning in predicting treatment outcomes in psychiatry. World Psychiatry. 2021;20(2):154–170.
   PubMed Web of Science ®Google Scholar